Salarius Pharmaceuticals Reports Director Changes and Compensation Updates

Ticker: DCOY · Form: 8-K · Filed: Oct 21, 2025 · CIK: 1615219

Sentiment: neutral

Topics: management-change, compensation

TL;DR

Salarius Pharma shakes up board, adjusts exec pay.

AI Summary

Salarius Pharmaceuticals, Inc. filed an 8-K on October 21, 2025, reporting changes in its board of directors and executive compensation arrangements. The filing indicates a shift in leadership and potential adjustments to how key personnel are compensated.

Why It Matters

Changes in a company's board and executive compensation can signal strategic shifts or financial restructuring, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect the company's strategic direction and financial stability.

Key Players & Entities

FAQ

What specific changes were made to the board of directors?

The filing indicates changes related to the 'Departure of Directors or Certain Officers' and 'Election of Directors', but the specific names and details of these changes are not provided in the excerpt.

What are the details of the compensatory arrangements for certain officers?

The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of disclosure, but the specific details of these arrangements are not included in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on October 21, 2025.

What is Salarius Pharmaceuticals, Inc.'s state of incorporation and IRS Employer Identification Number?

Salarius Pharmaceuticals, Inc. is incorporated in Delaware and its IRS Employer Identification Number is 46-5087339.

What was the former name of Salarius Pharmaceuticals, Inc. and when did the name change occur?

The former name of Salarius Pharmaceuticals, Inc. was Flex Pharma, Inc., and the date of the name change was July 30, 2014.

Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-10-21 11:57:52

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: October 21, 2025 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Acting Chief Executive Officer Executive Vice President & Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing